Veradermics, Incorporated (MANE)
| Market Cap | 2.85B |
| Revenue (ttm) | n/a |
| Net Income | -83.37M |
| EPS | -111.91 |
| Shares Out | 37.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 261,265 |
| Open | 75.00 |
| Previous Close | 74.12 |
| Day's Range | 74.55 - 77.31 |
| 52-Week Range | 32.00 - 80.90 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 78.33 (+2.67%) |
| Earnings Date | Mar 30, 2026 |
About MANE
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for MANE stock is "Strong Buy." The 12-month stock price target is $78.33, which is an increase of 2.67% from the latest price.
News
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
Veradermics to Participate in Upcoming March Investor Conferences
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the N...
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for comm...
Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Veradermics Announces Pricing of Upsized Initial Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative thera...
Veradermics, Dermatology Biopharma Focused on Hair Loss, Files for NYSE IPO
Veradermics, a late-stage dermatology biopharma, filed an S-1 for an initial public offering...
Veradermics IPO Registration Document (S-1)
Veradermics has filed to go public with an IPO on the New York Stock Exchange (NYSE)
Hair loss biotech Veradermics files for a $100 million IPO
Veradermics, a Phase 3-ready biotech developing therapies for hair loss, filed on Friday with the SEC to raise up to $100 million in an initial public offering.